Marlon Yovera-Aldana

Marlon Yovera-Aldana

Auto-generated profile, based on publicly available information

Marlon Yovera-Aldana

Affiliation Grupo de investigación de Neurociencias, Metabolismo, Efectividad Clínica y Sanitaria, Universidad Científica del Sur, Lima, Perú

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MYMarlon Yovera-Aldana
Marlon Yovera-Aldana
VVVictor Velásquez-Rimachi
Victor Velásquez-Rimachi
AHAndrely Huerta-Rosario
Andrely Huerta-Rosario
MMM. D. More-Yupanqui
M. D. More-Yupanqui
MOMariela Osores-Flores
Mariela Osores-Flores
KPKevin Pacheco-Barrios
Kevin Pacheco-Barrios
Aims: The objective of this systematic review and meta-analysis is to estimate the prevalence and incidence of diabetic peripheral neuropathy (DPN) in Latin America and the Caribbean (LAC). Materials and methods: We searched MEDLINE, SCOPUS, Web of Science, EMBASE and LILACS databases of published observational studies in LAC up to December 2020. Meta-analyses of proportions were performed using random-effects models using Stata Program 15.1. Heterogeneity was evaluated through sensitivity, subgroup, and meta-regression analyses. Evidence certainty was performed with the GRADE approach. Results: Twenty-nine studies from eight countries were included. The estimated prevalence of DPN was 46.5% (95%CI: 38.0–55.0) with a significant heterogeneity (I2 = 98.2%; p<0.01). Only two studies reported incidence, and the pooled effect size was 13.7% (95%CI: 10.6–17.2). We found an increasing trend of cumulative DPN prevalence over time. The main sources of heterogeneity associated with higher prevalence were diagnosis criteria, higher A1c (%), and inadequate sample size. We judge the included evidence as very low certainty. Conclusion: The overall prevalence of DPN is high in LAC with significant heterogeneity between and within countries that could be explained by population type and methodological aspects. Significant gaps (e.g., under-representation of most countries, lack of incidence studies, and heterogenous case definition) were identified. Standardized and population-based studies of DPN in LAC are needed.

28 November 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TMTania Maldonado-Valer
Tania Maldonado-Valer
LPLuis F Pareja-Mujica
Luis F Pareja-Mujica
RCRodrigo Corcuera-Ciudad
Rodrigo Corcuera-Ciudad
FTFernando Terry
Fernando Terry
MCMylenka Jennifer Chevarría-Arriaga
Mylenka Jennifer Chevarría-Arriaga
MYMarlon Yovera-Aldana
Marlon Yovera-Aldana
Aims: To determine the overall prevalence of diabetic foot at risk according to the International Working Group on the Diabetic Foot stratification. Materials and methods: We searched PubMed/Medline, Scopus, Web of Science, and Embase. We included cross-sectional studies or cohorts from 1999 to March 2022. We performed a meta-analysis of proportions using a random-effects model. We assessed heterogeneity through subgroup analysis by continent and other characteristics. Results: We included 36 studies with a total population of 11,850 people from 23 countries. The estimated overall prevalence of diabetic foot at risk was 53.2% (95% CI: 45.1–61.3), I2 = 98.7%, p < 0.001. In the analysis by subgroups, South and Central America had the highest prevalence and Africa the lowest. The factors explaining the heterogeneity were the presence of chronic kidney disease, diagnostic method for peripheral arterial disease, and quality. The estimates presented very low certainty of evidence. Conclusions: The overall prevalence of diabetic foot at risk is high. The high heterogeneity between continents can be explained by methodological aspects and the type of population. However, using the same classification is necessary for standardization of the way of measuring the components, as well as better designed general population-based studies.

1 June 2021 in Primary Care Diabetes
Verified
Journal Article
Closed access
MYMarlon Yovera-Aldana
Marlon Yovera-Aldana
SSSofia Sáenz-Bustamante
Sofia Sáenz-Bustamante
YQYudith Quispe-Landeo
Yudith Quispe-Landeo
RARosa Agüero-Zamora
Rosa Agüero-Zamora
JSJulia Salcedo
Julia Salcedo
David ArmstrongDavid Armstrong
David Armstrong

4 April 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SMSebastian A. Medina-Ramirez
Sebastian A. Medina-Ramirez
DSDavid R. Soriano-Moreno
David R. Soriano-Moreno
KTKimberly G. Tuco
Kimberly G. Tuco
SCSharong D. Castro-Diaz
Sharong D. Castro-Diaz
Rosa Alvarado-VillacortaRosa Alvarado-Villacorta
Rosa Alvarado-Villacorta
MYMarlon Yovera-Aldana
Marlon Yovera-Aldana
Objectives: This systematic review aimed to assess the prevalence and incidence of diabetic retinopathy in patients with diabetes of Latin America and the Caribbean. Methods: We searched Web of Science (WoS)/Core Collection, WoS/MEDLINE, WoS/Scielo, Scopus, PubMed/Medline and Embase databases until January 16, 2023. We meta-analyzed prevalences according to type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Results: Forty-three prevalence studies (47 585 participants) and one incidence study (436 participants) were included. The overall prevalence of retinopathy in patients with T1DM was 40.6% (95% CI: 34.7 to 46.6; I2: 92.1%) and in T2DM was 37.3% (95% CI: 31.0 to 43.8; I2: 97.7), but the evidence is very uncertain (very low certainty of evidence). In meta-regression, we found that age (T1DM) and time in diabetes (T2DM) were factors associated with the prevalence. On the other hand, one study found a cumulative incidence of diabetic retinopathy of 39.6% at 9 years of follow-up. Conclusions: Two out of five patients with T1DM or T2DM may present diabetic retinopathy in Latin America and the Caribbean, but the evidence is very uncertain. This is a major public health problem, and policies and strategies for early detection and opportunely treatment should be proposed.

7 August 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MYMarlon Yovera-Aldana
Marlon Yovera-Aldana
EMEdward Mezones-Holguín
Edward Mezones-Holguín
RARosa Agüero-Zamora
Rosa Agüero-Zamora
LDLucy Damas-Casani
Lucy Damas-Casani
BUBecky Uriol-Llanos
Becky Uriol-Llanos
RTRay Ticse-Aguirre
Ray Ticse-Aguirre
Aims: To evaluate the external validity of Finnish diabetes risk score (FINDRISC) and Latin American FINDRISC (LAFINDRISC) for undiagnosed dysglycemia in hospital health care workers. Methods: We carried out a cross-sectional study on health workers without a prior history of diabetes mellitus (DM). Undiagnosed dysglycemia (prediabetes or diabetes mellitus) was defined using fasting glucose and two-hour oral glucose tolerance test. LAFINDRISC is an adapted version of FINDRISC with different waist circumference cut-off points. We calculated the area under the receptor operational characteristic curve (AUROC) and explored the best cut-off point. Results: We included 549 participants in the analysis. The frequency of undiagnosed dysglycemia was 17.8%. The AUROC of LAFINDRISC and FINDRISC were 71.5% and 69.2%; p = 0.007, respectively. The optimal cut-off for undiagnosed dysglycemiaaccording to Index Youden was ≥ 11 in LAFINDRISC (Sensitivity: 78.6%; Specificity: 51.7%) and ≥12 in FINDRISC (Sensitivity: 70.4%; Specificity: 53.9%) Conclusion: The discriminative capacity of both questionnaires is good for the diagnosis of dysglycemia in the healthcare personnel of the María Auxiliadora hospital. The LAFINDRISC presented a small statistical difference, nontheless clinically similar, since there was no difference by age or sex. Further studies in the general population are required to validate these results.

4 June 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MYMarlon Yovera-Aldana
Marlon Yovera-Aldana
PSPaola Sifuentes-Hermenegildo
Paola Sifuentes-Hermenegildo
MCMartha Sofia Cervera-Ocaña
Martha Sofia Cervera-Ocaña
EMEdward Mezones-Holguin
Edward Mezones-Holguin
Objective: To evaluate the association of multidrug-resistant bacteria (MDRB) and adverse clinical outcomes in patients with diabetic foot infection (DFI) in a Peruvian hospital.Materials and methods: This retrospective cohort study evaluated patients treated in the Diabetic Foot Unit of a General Hospital in Lima, Peru. MDRB was defined by resistance to more than two pharmacological groups across six clinically significant genera. The primary outcome was death due to DFI complications and/or major amputation. Other outcomes included minor amputation, hospitalization, and a hospital stay longer than 14 days. Relative risks were estimated using Poisson regression for all outcomes.Results: The study included 192 DFI patients with a mean age of 59.9 years; 74% were males. A total of 80.8% exhibited MDRB. The primary outcome had an incidence rate of 23.2% and 5.4% in patients with and without MDRB, respectively (p = 0.01). After adjusting for sex, age, bone involvement, severe infection, ischemia, diabetes duration, and glycosylated hemoglobin, MDRB showed no association with the primary outcome (RR 3.29; 95% CI, 0.77–13.9), but did with hospitalization longer than 14 days (RR 1.43; 95% CI, 1.04–1.98).Conclusions: Our study found no association between MDRB and increased mortality and/or major amputation due to DFI complications, but did find a correlation with prolonged hospitalization. The high proportion of MDRB could limit the demonstration of the relationship. It is urgent to apply continuous evaluation of bacterial resistance, implement a rational plan for antibiotic use, and maintain biosafety to confront this threat.